A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

ClinicalTrials.gov ID: NCT00455013

Public ClinicalTrials.gov record NCT00455013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept (BMS-224818)-Based Corticosteroid-Free Regimens in Renal Transplant

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical research study is to learn if belatacept (BMS-224818) is expected to show acceptable rates of acute rejection (AR) in steroid-free belatacept-based immunosuppressive regiments compared to a similar steroid-free tacrolimus regimen. The long-term safety and tolerability of belatacept based regimens following long-term administration in subjects who have received a kidney transplant

Study identification

NCT ID: NCT00455013
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 93 participants

Conditions and interventions

Conditions

Disorder Related to Renal Transplantation

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2007
Primary completion: Sep 30, 2008
Completion: Jul 31, 2012
Last update posted: Jun 8, 2014

2007 – 2012

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
Ucsf	San Francisco	California	94143	—
Denver Nephrology, Pc	Denver	Colorado	80218	—
University Of Colorado Health Sciences Center	Denver	Colorado	80262	—
Medical College Of Georgia	Augusta	Georgia	30912	—
Northwestern University Feinberg School Of Medicine	Chicago	Illinois	60611	—
Henry Ford Hospital	Detriot	Michigan	48202	—
Albany Medical College	Albany	New York	12208	—
Carolinas Medical Center	Charlotte	North Carolina	28203	—
University Of Cincinnati	Cincinnati	Ohio	45267	—
Ohio State University Medical Center	Columbus	Ohio	43210	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00455013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 8, 2014 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00455013 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →